ASH 2023 | Add-on therapy with CK0804 for patients with MF who exhibit a suboptimal response to ruxolitinib
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on an ongoing Phase Ib, open-label study investigating an add-on therapy of CK0804 (CXCR4 enriched Tregs) in patients with myelofibrosis (MF) who have a suboptimal response to ruxolitinib alone. A preliminary analysis shows the initial safety profile as good, with no myelosuppressive adverse events and promising clinical activity. Additionally, Dr Masarova comments that the patients feel good and are happy to receive the treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: MorphoSys US
